

Celentyx Ltd News Release
8th December 2009



Alan Boyd appointed Honorary Professor at the University of Birmingham Medical School

BIRMINGHAM, UK – 8th December, 2009 – Celentyx Non-Executive Director Alan Boyd has been appointed Honorary Professor in the College of Medical and Dental Sciences at the University Medical School. Professor Boyd was awarded this honour in recognition for his valuable contribution over many years to the commercial activities of the University of Birmingham.

Professor Boyd has brought his wealth of industry expertise to the university. He was the Research & Development Director of Ark Therapeutics, a position he held from 1999 until 2005 (pre- & post-IPO) and has also held senior positions in the major pharma companies Glaxo and Zeneca, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

"We have been extremely fortunate to have benefited from Alan's experience and guidance since the early days of Celentyx, which is a spin-out from the University of Birmingham Medical School," commented Celentyx's CEO and Co-founder, Professor Nicholas Barnes. "He has been an important part of the success of the company and we are delighted that his contribution to the commercialisation activities of the University have been recognised".

About Celentyx Ltd

Celentyx is a pharmaceutical company focused on developing treatments for diseases of the human immune system.

Using our proprietary Immuno-Profiling™ platform, Celentyx has developed a pipeline of reprofiled drug candidates and has created an increasing portfolio of valuable drug targets upon human immune cells relevant for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia).

Our discovery services enable partners to identify new development paths for clinical-stage drug candidates, facilitate lead candidate prioritisation or identify any potentially negative impact of a drug on the human immune system. The company has established partnerships with a number of medium and large pharmaceutical companies.

For more information, please visit Celentyx's website at www.celentyx.com or contact:
Catherine Brady, PhD
Commercial Manager
E-mail: catherine.brady@celentyx.com